Viralytics Ltd Sp Ad (VRACY) 2.2000 $VRACY Viralytics to

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Viralytics Ltd Sp Ad (VRACY) 2.2000 $VRACY

Viralytics to present at two US institutional investor forums
PR Newswire - Fri Mar 07, 6:30AM CST
Viralytics Limited (ASX:VLA, OTC:VRACY) will present at two prominent U.S. healthcare investment conferences next week.

Target Enrollment Achieved in CAVATAK(TM) USA Phase 2 Melanoma Trial with Excellent Interim Results
PR Newswire - Wed Jan 08, 9:33AM CST
Viralytics Limited (ASX: VLA, OTCQX: VRACY) can report that the 54th late stage melanoma patient has been injected with CAVATAK(TM), thus achieving the major milestone of target enrolment in the US Phase 2 CALM trial.

Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2013
M2 - Mon Oct 07, 5:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dcg4xl/chronic) has announced the addition of the "Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2013" report to their offering. 'Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Chronic Lymphocytic Leukemia (CLL), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Chronic Lymphocytic Leukemia (CLL). Scope - A snapshot of the global therapeutic scenario for Chronic Lymphocytic Leukemia (CLL). - A review of the Chronic Lymphocytic Leukemia (CLL) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Chronic Lymphocytic Leukemia (CLL) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned - 4SC AG - Bayer AG - Celgene Corporation - Daiichi Sankyo Company, Ltd - Emergent BioSolutions Inc. - F. Hoffmann-La Roche Ltd. - Gedeon Richter Plc. - Hutchison MediPharma Limited - IMMUNOMEDICS, INC - KAEL-GemVax - LFB Biotechnologies, S.A.S.U. - MedImmune LLC - Novartis AG - Onconova Therapeutics, Inc - Panacea Biotec Limited - Sanofi-Aventis - Tragara Pharmaceuticals, Inc. - Viralytics Ltd. and many more... For more information visit http://www.researchandmarkets.com/research/dcg4xl/chronic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Primary Endpoint Achieved in CAVATAK Phase 2 Melanoma Trial
PR Newswire - Wed Sep 18, 6:33AM CDT
Viralytics Limited (ASX: VLA, OTCQX: VRACY) has achieved the primary endpoint in its Phase 2 clinical trial of CAVATAKTM in the treatment of late stage melanoma patients (the CALM study).

Bladder Cancer - Pipeline Review, H2 2013
M2 - Thu Sep 05, 8:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h66gxm/bladder_cancer) has announced the addition of the "Bladder Cancer - Pipeline Review, H2 2013" report to their offering. 'Bladder Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Bladder Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bladder Cancer. Scope - A snapshot of the global therapeutic scenario for Bladder Cancer. - A review of the Bladder Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Bladder Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Bladder Cancer. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Bladder Cancer pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Shionogi & Co., Ltd. Eli Lilly and Company Viralytics Ltd. GlaxoSmithKline plc Seattle Genetics, Inc. Bioniche Life Sciences, Inc. Bavarian Nordic A/S Biotest AG Samyang Corporation Eisai Co., Ltd. MDRNA, Inc. Taiho Pharmaceutical Co., Ltd. Advaxis, Inc. AEterna Zentaris Inc. Alnylam Pharmaceuticals, Inc Oncogenex Pharmaceuticals, Inc. and much more... For more information visit http://www.researchandmarkets.com/research/h6...der_cancer About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Global Melanoma Report - Pipeline Review
M2 - Tue Sep 03, 8:53AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tjxbsj/melanoma) has announced the addition of the "Melanoma - Pipeline Review, H2 2013" report to their offering. 'Melanoma - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Melanoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Melanoma. Scope - A snapshot of the global therapeutic scenario for Melanoma. - A review of the Melanoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Melanoma pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. 30 of the Companies Involved in Melanoma Therapeutics Development - Johnson & Johnson - Vical Incorporated - Amgen Inc. - AstraZeneca PLC - Eli Lilly and Company - Viralytics Ltd. - GlaxoSmithKline plc - Nektar Therapeutics - Antigenics, Inc. - Inovio Biomedical Corporation - medac GmbH - Merck & Co., Inc. - Lentigen Corporation - Generex Biotechnology Corporation - Plexxikon Inc. - Amorfix Life Sciences Ltd. - Prolexys Pharmaceuticals, Inc. - Aposense Ltd. - Histogen, Inc. - Novartis AG - Aphios Corporation - Daewoong Pharmaceutical Co., Ltd. - Eisai Co., Ltd. - Ono Pharmaceutical Co., Ltd. - Pfizer Inc. - SuperGen, Inc. - Teva Pharmaceutical Industries Limited - Alfacell Corporation - Bayer AG - MannKind Corporation For more information visit http://www.researchandmarkets.com/research/tjxbsj/melanoma

Viralytics Full Year Financial Results
PR Newswire - Tue Sep 03, 6:10AM CDT
Viralytics Limited (ASX:VLA, OTCQX:VRACY) has released its financial results for the year ended 30 June 2013.

Prostate Cancer - Pipeline Review, H2 2013
M2 - Mon Sep 02, 9:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tsvj5b/prostate_cancer) has announced the addition of the "Prostate Cancer - Pipeline Review, H2 2013" report to their offering. 'Prostate Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Prostate Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Prostate Cancer. Scope - A snapshot of the global therapeutic scenario for Prostate Cancer. - A review of the Prostate Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Prostate Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Bristol-Myers Squibb Company Johnson & Johnson Boehringer Ingelheim GmbH Celsion Corporation Amgen Inc. Sanofi-Aventis Adherex Technologies Inc. AstraZeneca PLC Eli Lilly and Company Viralytics Ltd. GlaxoSmithKline plc Bioniche Life Sciences, Inc. Genentech, Inc. Inovio Biomedical Corporation Bavarian Nordic A/S Isis Pharmaceuticals, Inc. Biotest AG GenVec, Inc. Merck & Co., Inc. AbGenomics International, Inc. Emergent BioSolutions Inc. Oxford BioMedica plc and many more... For more information visit http://www.researchandmarkets.com/research/ts...ate_cancer About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Viralytics to present at 15th Annual Rodman & Renshaw Global Investment Conference
PR Newswire - Tue Aug 27, 6:10AM CDT
Viralytics Limited (ASX: VLA, OTCQX: VRACY) is pleased to announce that Dr Malcolm McColl, Chief Executive Officer will be presenting at the 15th Annual Rodman & Renshaw Global Investment Conference, Millennium Broadway Hotel, New York.

Viralytics Ltd. Begins Trading on OTCQX®
PR Newswire - Mon Aug 05, 6:00AM CDT
OTC Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and Connected financial marketplaces, today announced that Viralytics Ltd. (OTCQX: VRACY; ASX: VLA), a biotechnology company, has qualified to have its American Depositary Receipts (ADRs) traded on OTCQX®, the best marketplace with qualified companies.

Viralytics Advances CAVATAK(TM) Clinical Programs in Late Stage Melanoma, Prostate, Breast and Colorectal Cancers
PR Newswire - Mon Jul 29, 6:03AM CDT
Viralytics Limited (ASX: VLA; OTC: VRACY), an oncolytic virotherapy company developing new drugs to treat a wide range of cancers, today announced that progress in its Phase 2 clinical trial of intratumourally administered CAVATAK(TM) for the treatment of late-stage melanoma (the CALM study) continues to accelerate with the recent reporting of strong interim results at the 8th World Congress of Melanoma, Hamburg, Germany.

Pancreatic Cancer - Pipeline Review, H1 2013 Gives a Snapshot of the Global Therapeutic Scenario for Pancreatic Cancer
M2 - Wed Jun 05, 9:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/g6cvrj/pancreatic_cancer) has announced the addition of the "Pancreatic Cancer - Pipeline Review, H1 2013" report to their offering. Global Markets Direct's, 'Pancreatic Cancer - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Pancreatic Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Pancreatic Cancer. Pancreatic Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A review of the Pancreatic Cancer products under dev

Gynecological Cancer - Pipeline Review, H1 2013 Features Players such as Amgen Inc., Bionomics Limited and Novogen Limited
M2 - Wed Jun 05, 9:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2rhvd5/gynecological) has announced the addition of the "Gynecological Cancer - Pipeline Review, H1 2013" report to their offering. Global Markets Direct's, 'Gynecological Cancer - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Gynecological Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Gynecological Cancer. Gynecological Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scen

Viralytics Ltd. - Product Pipeline Review - 2012
M2 - Mon Feb 18, 3:57AM CST
Summary

2013 Melanoma Global Clinical Trials Review
M2 - Wed Jan 30, 4:03AM CST
Research and Markets (http://www.researchandmarkets.com/research/hsdlwn/melanoma_global) has announced the addition of GlobalData's new report "Melanoma Global Clinical Trials Review, H1, 2013" to their offering. This report provides elemental information and data relating to the clinical trials on Melanoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Melanoma. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributi

Intestinal Cancer - Pipeline Review, H2 2012 Includes a Snapshot of the Global Therapeutic Scenario for Intestinal Cancer
M2 - Thu Jan 17, 10:48AM CST
Research and Markets (http://www.researchandmarkets.com/research/qkchs6/intestinal_cancer) has announced the addition of Global Markets Direct's new report "Intestinal Cancer - Pipeline Review, H2 2012" to their offering. Global Markets Direct's, 'Intestinal Cancer - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Intestinal Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Intestinal Cancer. Intestinal Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Normal 0 false false false MicrosoftI

Blood Cancer - Pipeline Review, H2 2012 Report Features Players such as Boehringer Ingelheim GmbH and Amgen Inc.
M2 - Thu Jan 17, 10:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/5j8jnc/blood_cancer) has announced the addition of Global Markets Direct's new report "Blood Cancer - Pipeline Review, H2 2012" to their offering. Global Markets Direct's, 'Blood Cancer - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Blood Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Blood Cancer. Blood Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Blood Ca
Scroll down for more posts ▼

Top 10 Most Recent News Articles

LG Channels UAE Push Tests the Free Streaming Model

Updated Category News Views 137

A television's idle screen is turning into contested real estate in the UAE. LG Channels is adding programming from Rakuten TV, Stingray and Red Bull TV to its free, ad-supported service, and that matters for more than somebody hunting a movie after dinner. This is a practical push to make webOS-powered screens more useful, more frequently used and, eventually, more...

Continue Reading
Condo Downsizing Demands More Than a Price Check Today

Updated Category News Views 58

A smaller front door can hide a surprisingly large stack of obligations. That is the useful point in the HelloNation guidance featuring Chevy Chase real estate expert Lise Howe: downsizing into a condo is not merely a square-footage trade. It is a decision about recurring costs, building stewardship, daily friction, and whether the place still works when life gets less...

Continue Reading
Housing's Value Equation Is Getting More Complicated

Updated Category News Views 58

A homeowner's insurance bill has become a louder market signal than a granite countertop. Green Builder Media's latest batch of research, publishing and events is aimed squarely at that uncomfortable truth: housing is no longer judged only by the price on the contract. Buyers, builders, lenders and insurers are being pushed to reckon with what a home costs to own, protect...

Continue Reading
Leqembi’s Real-World Data Gives BioArctic More Weight

Updated Category News Views 133

A Harder Look at Treatment Staying Power Alzheimer’s drug data rarely arrive without a thicket of caveats, and that is exactly why this Leqembi update deserves a calm read rather than a victory lap. BioArctic’s partner Eisai presented a three-year real-world analysis at CTAD 2026 covering 560 early Alzheimer’s patients across 13 U.S. sites. The headline is striking:...

Continue Reading
Yoodli's No. 9 Ranking Signals Enterprise AI Traction

Updated Category News Views 58

Ninth place can be easy to dismiss until you notice the company is sitting near the top of a 500-name growth list. Yoodli's No. 9 position on Deloitte's 2026 Technology Fast 500 is a meaningful signal that its AI-based coaching and workforce-skills pitch is getting traction inside large organizations. It is not a revenue disclosure, it is not a valuation marker, and...

Continue Reading
MetaOptics Tests a Real Path Into Secure Imaging Markets

Updated Category News Views 68

Fingerprint scanners have never impressed me much; fooling one is exactly the sort of nuisance that keeps security buyers spending. MetaOptics’ new collaboration with Hong Kong’s ASTRI goes after that uncomfortable problem with a compact nano-optics imaging system built for biometric security and smart sensing. It is a sensible target. It is also, at this stage, a...

Continue Reading
TGHL Eyes U.S. Battery Shift Through EnChem Merger

Updated Category News Views 159

A Policy Squeeze Is Rewriting the Battery Map Battery supply chains are getting shoved through a narrower gate, and that is exactly why this proposed deal deserves a hard look. The GrowHub Limited wants to acquire EnChem America, a Georgia-based lithium-ion battery electrolyte producer, and the timing is plainly built around Washington's push to reduce reliance on...

Continue Reading
Clarivate's 2026 Research List Carries a Trust Test

Updated Category News Views 254

Seven thousand ninety awards can look like a victory lap until you remember how easily raw citation counts can be gamed. Clarivate’s 2026 Highly Cited Researchers list is more interesting for its insistence on screening than for the familiar names at the top. In a research world where publication volume, self-citation and paper mills have made plenty of people...

Continue Reading
Mar-Jac's Safety Milestone Carries Real Operational Weight

Updated Category News Views 62

Four million worked hours without a lost-time accident is the sort of number that ought to make people pause, especially in poultry processing. Mar-Jac Poultry’s Gainesville facility earned Workplace Safety recognition from the Greater Hall Chamber of Commerce after reaching that mark, and this is one corporate achievement that deserves a little less eye-rolling than...

Continue Reading
Tim Hortons Bets on ELF Cheer for U.S. Holiday Visits

Updated Category News Views 35

Nothing says holiday restaurant marketing quite like putting spaghetti-shaped whipped topping on hot chocolate and trusting a 2003 movie to do the selling. Tim Hortons is rolling out an ELF-inspired menu at participating U.S. locations starting November 18, 2026, pairing the chain with Warner Bros. Consumer Products and mining Buddy the Elf's sugar-fueled world for a...

Continue Reading

Top 5 Most Recently Viewed Articles

T&T Supermarkets Expands Presence with New Store Opening

Updated Category News Views 466

T&T Supermarkets Unveils Plans for a Major New Store T&T Supermarket Inc., Canada's largest Asian grocery retailer, is excited to share plans for their newest store in California, which will be located at Crossroads Marketplace in Chino Hills. This store will span an impressive 61,000 square feet, providing ample space for a wide variety of products and services to meet...

Continue Reading
Autohome Inc. Unveils its Comprehensive 2024 ESG Report

Updated Category News Views 268

Autohome Inc. Releases 2024 ESG Report Autohome Inc. (NYSE: ATHM) has shared its 2024 Environmental, Social, and Governance (ESG) report. This document emphasizes the firm's commitment to sustainable practices and highlights their ongoing journey towards eco-friendly solutions within the automobile sector. Insights from the ESG Report The report details the extensive ESG...

Continue Reading
Nintendo and The Pokemon Company Pursue Legal Action Against Palworld

Updated Category News Views 87

Nintendo and The Pokemon Company Take Legal Action Nintendo and The Pokemon Company have officially initiated a patent infringement lawsuit against the creators of the popular survival adventure game, "Palworld." This development has caught the attention of both gamers and industry experts alike. Details of the Lawsuit Reports indicate that the lawsuit was filed on...

Continue Reading
NYCM Insurance Achieves Elite Winner Status for Wellness

Updated Category News Views 118

NYCM Insurance Celebrated for Wellness Excellence NYCM Insurance proudly announces its recognition as an "Elite Winner" among the Nation's Best and Brightest in Wellness. This marks an outstanding milestone for the company, achieving the accolade for the twelfth consecutive year, a testament to their dedication to enhancing employee wellness. Commitment to Employee...

Continue Reading
Antonio Filosa Leads Stellantis with Newly Formed Team

Updated Category News Views 284

New Leadership Structure at Stellantis Under Antonio Filosa Today marks a significant milestone for Stellantis N.V. as Antonio Filosa steps into the role of Chief Executive Officer. Alongside this transition, he has unveiled an exciting new leadership team, showcasing a strong lineup of industry veterans and decision-makers from across Stellantis’ diverse operations...

Continue Reading